| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.802 | 0.002 | 0.84 | HIV-1 integrase inhibitor | 0.56 0.002 DBMET01875 0.535 0.003 DBMET01871 0.694 0.002 DBMET01872 0.58 0.002 DBMET01874 0.167 0.006 DBMET03561 0.84 0.002 DBMET01873 | DBMET01873 | |
| 0.298 | 0.026 | 0.354 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.236 0.086 DBMET01875 0.229 0.098 DBMET01871 0.268 0.046 DBMET01872 0.236 0.086 DBMET01874 0.354 0.011 DBMET01873 | DBMET01873 | |
| 0.358 | 0.086 | 0.448 | MAP kinase kinase 6 inhibitor | 0.245 0.197 DBMET01875 0.306 0.13 DBMET01872 0.448 0.035 DBMET01873 | DBMET01873 | |
| 0.248 | 0.068 | 0.381 | DNA synthesis inhibitor | 0.381 0.024 DBMET01871 0.205 0.115 DBMET01872 0.369 0.027 DBMET03561 0.358 0.029 DBMET01873 | DBMET01871 | |
| 0.227 | 0.139 | 0.227 | Ca(v)3.3 blocker | |||
| 0.142 | 0.079 | 0.169 | MAP kinase kinase 4 inhibitor | 0.139 0.087 DBMET01872 0.16 0.044 DBMET03561 0.169 0.034 DBMET01873 | DBMET01873 | |
| 0.182 | 0.123 | 0.441 | Nitric-oxide synthase stimulant | 0.196 0.096 DBMET01871 0.441 0.003 DBMET03561 | DBMET03561 | |
| 0.121 | 0.079 | 0.121 | Papain-like protease (SARS coronavirus) inhibitor | |||
| 0.096 | 0.091 | 0.096 | Electron transport complex I inhibitor | |||
| 0.094 | 0.092 | 0.13 | DNA polymerase I inhibitor | 0.128 0.063 DBMET01871 0.13 0.061 DBMET01873 | DBMET01873 | |
| 0.021 | 0.046 | 0.032 | Potassium channel subfamily K member 3 blocker | 0.032 0.019 DBMET03561 | DBMET03561 | |
| 0.064 | 0.136 | 0.243 | Topoisomerase II inhibitor | 0.243 0.025 DBMET01871 | DBMET01871 | |
| 0.039 | 0.115 | 0.114 | CDC25B inhibitor | 0.114 0.012 DBMET03561 | DBMET03561 | |
| 0.054 | 0.131 | 0.077 | Antineoplastic alkaloid | 0.077 0.069 DBMET01873 | DBMET01873 | |
| 0.179 | 0.257 | 0.592 | Antibacterial | 0.274 0.156 DBMET01875 0.592 0.02 DBMET01871 0.241 0.186 DBMET01874 0.247 0.179 DBMET03561 0.392 0.081 DBMET01873 | DBMET01871 | |
| 0.047 | 0.179 | 0.104 | Protein kinase C mu inhibitor | 0.104 0.053 DBMET01873 | DBMET01873 | |
| 0.177 | 0.31 | 0.474 | Apoptosis agonist | 0.32 0.158 DBMET01875 0.474 0.082 DBMET01871 0.267 0.198 DBMET01874 0.269 0.196 DBMET01873 | DBMET01871 | |
| 0.126 | 0.269 | 0.162 | MAP kinase kinase 5 inhibitor | 0.162 0.108 DBMET01873 | DBMET01873 | |
| 0.037 | 0.189 | 0.095 | Potassium channel (Tandem pore domain) blocker | 0.095 0.012 DBMET03561 | DBMET03561 | |
| 0.095 | 0.255 | 0.145 | Lipocortins synthesis antagonist | 0.145 0.113 DBMET03561 | DBMET03561 | |
| 0.124 | 0.289 | 0.297 | Peptidyltransferase inhibitor | 0.297 0.026 DBMET01871 0.225 0.071 DBMET01873 | DBMET01871 | |
| 0.033 | 0.215 | 0.061 | Adenine nucleotide translocase inhibitor | 0.061 0.026 DBMET03561 | DBMET03561 | |
| 0.139 | 0.329 | 0.411 | Interleukin 2 agonist | 0.228 0.145 DBMET01875 0.305 0.07 DBMET01871 0.209 0.175 DBMET01874 0.411 0.024 DBMET03561 | DBMET03561 | |
| 0.017 | 0.213 | 0.063 | Protein 50S ribosomal subunit inhibitor | 0.063 0.029 DBMET01871 | DBMET01871 | |
| 0.029 | 0.237 | 0.207 | Topoisomerase I inhibitor | 0.207 0.025 DBMET01871 | DBMET01871 | |
| 0.026 | 0.241 | 0.057 | Antiviral (Hepatitis D) | 0.057 0.026 DBMET03561 | DBMET03561 | |
| 0.026 | 0.242 | 0.07 | CDC25A inhibitor | 0.07 0.057 DBMET03561 | DBMET03561 | |
| 0.006 | 0.226 | 0.06 | Antimetabolite | 0.06 0.025 DBMET03561 | DBMET03561 | |
| 0.01 | 0.231 | 0.028 | Integrin alpha2beta1 antagonist | 0.028 0.014 DBMET03561 | DBMET03561 | |
| 0.068 | 0.291 | 0.255 | NOS3 expression enhancer | 0.152 0.07 DBMET01871 0.255 0.025 DBMET03561 | DBMET03561 | |
| 0.013 | 0.239 | 0.071 | Antineoplastic antibiotic | 0.071 0.064 DBMET01871 | DBMET01871 | |
| 0.017 | 0.244 | 0.103 | 5 Hydroxytryptamine 2A agonist | 0.103 0.013 DBMET03561 | DBMET03561 | |
| 0.097 | 0.328 | 0.169 | MAP-kinase-activated kinase 5 inhibitor | 0.169 0.149 DBMET01873 | DBMET01873 | |
| 0.025 | 0.262 | 0.202 | Sodium/calcium exchanger inhibitor | 0.202 0.003 DBMET03561 | DBMET03561 | |
| 0.061 | 0.303 | 0.157 | Transcription factor STAT6 inhibitor | 0.157 0.019 DBMET03561 | DBMET03561 | |
| 0.006 | 0.253 | 0.044 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.044 0.019 DBMET03561 | DBMET03561 | |
| 0.004 | 0.251 | 0.082 | Uridine phosphorylase inhibitor | 0.082 0.003 DBMET03561 | DBMET03561 | |
| 0.016 | 0.266 | 0.047 | Antibiotic Aminoglycoside-like | 0.047 0.015 DBMET01871 | DBMET01871 | |
| 0.044 | 0.299 | 0.143 | Transcription factor NF kappa B stimulant | 0.086 0.058 DBMET01871 0.143 0.017 DBMET03561 | DBMET03561 | |
| 0.038 | 0.3 | 0.116 | MAP kinase 13 inhibitor | 0.116 0.06 DBMET03561 | DBMET03561 | |
| 0.012 | 0.28 | 0.038 | Integrin alpha2 antagonist | 0.038 0.024 DBMET03561 | DBMET03561 | |
| 0.007 | 0.276 | 0.071 | Guanylate cyclase 1 stimulant | 0.071 0.004 DBMET03561 | DBMET03561 | |
| 0.009 | 0.285 | 0.058 | Thymidylate synthase inhibitor | 0.058 0.018 DBMET03561 | DBMET03561 | |
| 0.016 | 0.298 | 0.068 | Protein kinase C beta inhibitor | 0.068 0.053 DBMET03561 0.065 0.058 DBMET01873 | DBMET03561 | |
| 0.092 | 0.378 | 0.12 | CC chemokine 6 receptor antagonist | 0.12 0.117 DBMET01871 | DBMET01871 | |
| 0.045 | 0.333 | 0.141 | Glutamate (mGluR7) agonist | 0.141 0.016 DBMET03561 | DBMET03561 | |
| 0.007 | 0.295 | 0.023 | 5 Hydroxytryptamine 1F agonist | 0.023 0.021 DBMET03561 | DBMET03561 | |
| 0.005 | 0.297 | 0.019 | 4-Hydroxyphenylpyruvate dioxygenase inhibitor | 0.019 0.004 DBMET03561 | DBMET03561 | |
| 0.013 | 0.306 | 0.106 | Alpha-mannosidase inhibitor | 0.106 0.005 DBMET03561 | DBMET03561 | |
| 0.017 | 0.322 | 0.137 | Guanylate cyclase stimulant | 0.137 0.005 DBMET03561 | DBMET03561 | |
| 0.005 | 0.31 | 0.047 | HMG CoA reductase inhibitor | 0.047 0.009 DBMET03561 | DBMET03561 | |
| 0.052 | 0.367 | 0.441 | Interleukin agonist | 0.169 0.15 DBMET01871 0.441 0.014 DBMET03561 | DBMET03561 | |
| 0.043 | 0.369 | 0.154 | MAP3K9 inhibitor | 0.154 0.055 DBMET03561 | DBMET03561 | |
| 0.008 | 0.338 | 0.065 | Aldose reductase inhibitor | 0.065 0.03 DBMET03561 | DBMET03561 | |
| 0.011 | 0.348 | 0.472 | p38 MAP kinase inhibitor | 0.472 0.005 DBMET03561 | DBMET03561 | |
| 0.035 | 0.372 | 0.145 | Nav1.4 sodium channel blocker | 0.145 0.036 DBMET03561 | DBMET03561 | |
| 0.008 | 0.364 | 0.093 | Mannosidase inhibitor | 0.093 0.006 DBMET03561 | DBMET03561 | |
| 0.015 | 0.378 | 0.056 | Acetyl-CoA transferase 2 inhibitor | 0.056 0.041 DBMET03561 | DBMET03561 | |
| 0.015 | 0.381 | 0.197 | Nav1.8 sodium channel blocker | 0.197 0.008 DBMET03561 | DBMET03561 | |
| 0.036 | 0.403 | 0.295 | Aldehyde dehydrogenase inhibitor | 0.295 0.012 DBMET03561 | DBMET03561 | |
| 0.015 | 0.383 | 0.034 | Glutamate (mGluR8) antagonist | 0.034 0.03 DBMET03561 | DBMET03561 | |
| 0.009 | 0.381 | 0.482 | MAP kinase 14 inhibitor | 0.482 0.004 DBMET03561 | DBMET03561 | |
| 0.008 | 0.383 | 0.081 | TRPA1 antagonist | 0.081 0.025 DBMET03561 | DBMET03561 | |
| 0.013 | 0.39 | 0.139 | MAP kinase 11 inhibitor | 0.139 0.02 DBMET03561 | DBMET03561 | |
| 0.006 | 0.384 | 0.058 | Potassium channel KCNQ activator | 0.058 0.011 DBMET03561 | DBMET03561 | |
| 0.006 | 0.384 | 0.058 | Delayed rectifier potassium channel activator | 0.058 0.011 DBMET03561 | DBMET03561 | |
| 0.028 | 0.407 | 0.153 | MAP kinase 12 inhibitor | 0.153 0.04 DBMET03561 | DBMET03561 | |
| 0.12 | 0.511 | 0.441 | Calcium channel L-type activator | 0.441 0.056 DBMET03561 | DBMET03561 | |
| 0.016 | 0.418 | 0.168 | Topoisomerase II alpha inhibitor | 0.168 0.02 DBMET01871 | DBMET01871 | |
| 0.009 | 0.42 | 0.068 | Ceramide glucosyltransferase inhibitor | 0.068 0.003 DBMET03561 | DBMET03561 | |
| 0.007 | 0.42 | 0.078 | Glycine transporter 2 inhibitor | 0.078 0.018 DBMET03561 | DBMET03561 | |
| 0.051 | 0.467 | 0.164 | MAP kinase 3 inhibitor | 0.164 0.049 DBMET03561 | DBMET03561 | |
| 0.009 | 0.431 | 0.026 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.026 0.019 DBMET03561 | DBMET03561 | |
| 0.028 | 0.455 | 0.164 | Dual specificity phosphatase 3 inhibitor | 0.164 0.085 DBMET03561 | DBMET03561 | |
| 0.013 | 0.441 | 0.099 | Secretase beta inhibitor | 0.099 0.018 DBMET03561 | DBMET03561 | |
| 0.008 | 0.445 | 0.055 | Endothelin-converting enzyme inhibitor | 0.055 0.027 DBMET03561 | DBMET03561 | |
| 0.014 | 0.455 | 0.06 | CF transmembrane conductance regulator antagonist | 0.06 0.004 DBMET03561 | DBMET03561 | |
| 0.012 | 0.457 | 0.038 | Potassium channel Kv1.1 blocker | 0.038 0.026 DBMET03561 | DBMET03561 | |
| 0.023 | 0.47 | 0.068 | Bcl-xL inhibitor | 0.067 0.024 DBMET01875 0.068 0.023 DBMET01874 | DBMET01874 | |
| 0.045 | 0.492 | 0.216 | Hepatoprotectant | 0.216 0.056 DBMET01871 0.179 0.08 DBMET03561 | DBMET01871 | |
| 0.004 | 0.455 | 0.149 | Secretase gamma inhibitor | 0.149 0.004 DBMET01872 0.102 0.006 DBMET03561 | DBMET01872 | |
| 0.012 | 0.468 | 0.13 | Potassium channel (Voltage-sensitive) activator | 0.13 0.024 DBMET03561 | DBMET03561 | |
| 0.008 | 0.466 | 0.046 | Mineralocorticoid receptor antagonist | 0.046 0.036 DBMET03561 | DBMET03561 | |
| 0.008 | 0.466 | 0.036 | Retinoic acid alpha receptor agonist | 0.036 0.033 DBMET03561 | DBMET03561 | |
| 0.012 | 0.474 | 0.039 | Thiazolidinedione | 0.039 0.009 DBMET03561 | DBMET03561 | |
| 0.016 | 0.478 | 0.116 | Potassium channel activator | 0.116 0.035 DBMET03561 | DBMET03561 | |
| 0.026 | 0.492 | 0.134 | Dual specificity phosphatase inhibitor | 0.134 0.114 DBMET03561 | DBMET03561 | |
| 0.004 | 0.475 | 0.021 | Leukotriene B4 receptor 2 antagonist | 0.021 0.017 DBMET03561 | DBMET03561 | |
| 0.003 | 0.477 | 0.07 | Prostaglandin EP3 antagonist | 0.07 0.007 DBMET03561 | DBMET03561 | |
| 0.002 | 0.484 | 0.03 | Cyclin T1 inhibitor | 0.03 0.005 DBMET03561 | DBMET03561 | |
| 0.004 | 0.487 | 0.056 | 5 Hydroxytryptamine 2 agonist | 0.056 0.031 DBMET03561 | DBMET03561 | |
| 0.004 | 0.488 | 0.033 | Prostaglandin D2 agonist | 0.033 0.019 DBMET03561 | DBMET03561 | |
| 0.025 | 0.51 | 0.082 | MAP kinase kinase 7 inhibitor | 0.082 0.04 DBMET03561 0.078 0.051 DBMET01873 | DBMET03561 | |
| 0.023 | 0.519 | 0.351 | Angiogenesis stimulant | 0.351 0.032 DBMET01871 | DBMET01871 | |
| 0.012 | 0.513 | 0.069 | Orexin receptor 1 antagonist | 0.069 0.059 DBMET03561 | DBMET03561 | |
| 0.1 | 0.601 | 0.196 | MAP kinase kinase 3 inhibitor | 0.196 0.135 DBMET01873 | DBMET01873 | |
| 0.002 | 0.503 | 0.071 | Prostaglandin E2 agonist | 0.071 0.005 DBMET03561 | DBMET03561 | |
| 0.009 | 0.513 | 0.059 | AICAR transformylase inhibitor | 0.059 0.015 DBMET03561 | DBMET03561 | |
| 0.023 | 0.526 | 0.469 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.469 0.003 DBMET03561 | DBMET03561 | |
| 0.008 | 0.515 | 0.042 | Dipeptidyl peptidase IV inhibitor | 0.042 0.035 DBMET03561 | DBMET03561 | |
| 0.002 | 0.51 | 0.017 | Complement factor D inhibitor | 0.017 0.016 DBMET03561 | DBMET03561 | |
| 0.025 | 0.537 | 0.097 | Thioredoxin reductase inhibitor | 0.097 0.031 DBMET03561 | DBMET03561 | |
| 0.008 | 0.52 | 0.047 | MAP3K5 inhibitor | 0.047 0.015 DBMET03561 | DBMET03561 | |
| 0.003 | 0.515 | 0.042 | Free fatty acid receptor 1 agonist | 0.042 0.005 DBMET03561 | DBMET03561 | |
| 0.031 | 0.544 | 0.154 | Nitric oxide antagonist | 0.154 0.091 DBMET01871 | DBMET01871 | |
| 0.009 | 0.527 | 0.076 | Leukotriene synthesis inhibitor | 0.076 0.039 DBMET03561 | DBMET03561 | |
| 0.009 | 0.53 | 0.049 | Dipeptidyl peptidase inhibitor | 0.049 0.046 DBMET03561 | DBMET03561 | |
| 0.012 | 0.533 | 0.092 | GABA A receptor agonist | 0.092 0.045 DBMET03561 | DBMET03561 | |
| 0.016 | 0.54 | 0.243 | UDP-glucose 4-epimerase inhibitor | 0.243 0.014 DBMET03561 | DBMET03561 | |
| 0.053 | 0.578 | 0.296 | Nootropic | 0.296 0.076 DBMET03561 | DBMET03561 | |
| 0.037 | 0.564 | 0.085 | CC chemokine 5 receptor agonist | 0.085 0.049 DBMET03561 | DBMET03561 | |
| 0.006 | 0.535 | 0.067 | Glucagon-like peptide 1 agonist | 0.067 0.043 DBMET03561 | DBMET03561 | |
| 0.006 | 0.535 | 0.075 | Androgen agonist | 0.075 0.027 DBMET03561 | DBMET03561 | |
| 0.013 | 0.552 | 0.077 | Autotaxin inhibitor | 0.077 0.02 DBMET03561 | DBMET03561 | |
| 0.005 | 0.546 | 0.07 | Benzodiazepine agonist | 0.07 0.051 DBMET03561 | DBMET03561 | |
| 0.017 | 0.561 | 0.131 | Thrombolytic | 0.131 0.098 DBMET01871 | DBMET01871 | |
| 0.026 | 0.571 | 0.242 | Antioxidant | 0.242 0.088 DBMET01871 | DBMET01871 | |
| 0.008 | 0.557 | 0.104 | Sphingosine 1-phosphate receptor 3 antagonist | 0.104 0.007 DBMET03561 | DBMET03561 | |
| 0.008 | 0.562 | 0.019 | Granulocyte colony stimulating factor receptor agonist | 0.019 0.011 DBMET03561 | DBMET03561 | |
| 0.002 | 0.557 | 0.087 | Prostaglandin agonist | 0.087 0.006 DBMET03561 | DBMET03561 | |
| 0.009 | 0.567 | 0.04 | Thymidine kinase inhibitor | 0.04 0.03 DBMET03561 | DBMET03561 | |
| 0.014 | 0.574 | 0.071 | Topoisomerase II beta inhibitor | 0.071 0.016 DBMET03561 | DBMET03561 | |
| 0.049 | 0.61 | 0.383 | Analgesic | 0.383 0.092 DBMET03561 | DBMET03561 | |
| 0.003 | 0.565 | 0.071 | Guanylate cyclase inhibitor | 0.071 0.005 DBMET03561 | DBMET03561 | |
| 0.001 | 0.568 | 0.022 | Prostaglandin EP4 agonist | 0.022 0.008 DBMET03561 | DBMET03561 | |
| 0.016 | 0.584 | 0.145 | Anticoagulant | 0.145 0.085 DBMET01871 | DBMET01871 | |
| 0.011 | 0.579 | 0.085 | Caspase 7 inhibitor | 0.085 0.051 DBMET03561 | DBMET03561 | |
| 0.004 | 0.574 | 0.112 | Glutamate (mGluR5) agonist | 0.112 0.005 DBMET03561 | DBMET03561 | |
| 0.064 | 0.634 | 0.555 | Antiinflammatory | 0.396 0.142 DBMET01871 0.555 0.067 DBMET03561 | DBMET03561 | |
| 0.01 | 0.581 | 0.103 | Phospholipase D inhibitor | 0.103 0.013 DBMET03561 | DBMET03561 | |
| 0.032 | 0.607 | 0.201 | Histone acetyltransferase inhibitor | 0.201 0.068 DBMET03561 | DBMET03561 | |
| 0.012 | 0.588 | 0.118 | GABA receptor agonist | 0.118 0.059 DBMET03561 | DBMET03561 | |
| 0.013 | 0.594 | 0.098 | Interleukin 1 beta converting enzyme inhibitor | 0.098 0.06 DBMET03561 | DBMET03561 | |
| 0.023 | 0.607 | 0.203 | Lanosterol 14 alpha demethylase inhibitor | 0.203 0.004 DBMET03561 | DBMET03561 | |
| 0.008 | 0.593 | 0.161 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.161 0.005 DBMET03561 | DBMET03561 | |
| 0.018 | 0.606 | 0.089 | Thioredoxin inhibitor | 0.089 0.063 DBMET03561 | DBMET03561 | |
| 0.013 | 0.601 | 0.097 | 5 Hydroxytryptamine 3A agonist | 0.097 0.08 DBMET03561 | DBMET03561 | |
| 0.02 | 0.612 | 0.242 | Cell wall synthesis inhibitor | 0.242 0.017 DBMET03561 | DBMET03561 | |
| 0.005 | 0.601 | 0.094 | Protein-tyrosine phosphatase 1B inhibitor | 0.094 0.085 DBMET03561 | DBMET03561 | |
| 0.038 | 0.635 | 0.399 | Hypoglycemic | 0.284 0.059 DBMET01871 0.399 0.028 DBMET03561 | DBMET03561 | |
| 0.005 | 0.602 | 0.048 | 5 Hydroxytryptamine 2B agonist | 0.048 0.015 DBMET03561 | DBMET03561 | |
| 0.003 | 0.601 | 0.069 | Phosphorylase inhibitor | 0.069 0.02 DBMET03561 | DBMET03561 | |
| 0.003 | 0.604 | 0.14 | Prostaglandin EP1 antagonist | 0.14 0.004 DBMET03561 | DBMET03561 | |
| 0.022 | 0.624 | 0.147 | Toll-Like receptor 4 antagonist | 0.147 0.023 DBMET03561 | DBMET03561 | |
| 0.004 | 0.606 | 0.136 | Glutamate (mGluR group I) agonist | 0.136 0.005 DBMET03561 | DBMET03561 | |
| 0.005 | 0.607 | 0.041 | Liver X receptor alpha antagonist | 0.041 0.009 DBMET03561 | DBMET03561 | |
| 0.048 | 0.654 | 0.2 | Sodium/bile acid cotransporter inhibitor | 0.2 0.188 DBMET01874 | DBMET01874 | |
| 0.002 | 0.609 | 0.058 | Estradiol 17 beta-dehydrogenase inhibitor | 0.058 0.021 DBMET03561 | DBMET03561 | |
| 0.03 | 0.639 | 0.398 | Antiobesity | 0.398 0.066 DBMET03561 | DBMET03561 | |
| 0.004 | 0.615 | 0.105 | Prostaglandin EP2 antagonist | 0.105 0.018 DBMET03561 | DBMET03561 | |
| 0.004 | 0.617 | 0.035 | Kinesin antagonist | 0.035 0.028 DBMET01875 | DBMET01875 | |
| 0.004 | 0.617 | 0.035 | Kinesin-like protein 1 inhibitor | 0.035 0.028 DBMET01875 | DBMET01875 | |
| 0.015 | 0.629 | 0.19 | Free radical scavenger | 0.19 0.106 DBMET01871 | DBMET01871 | |
| 0.003 | 0.617 | 0.043 | Sodium/glucose cotransporter inhibitor | 0.043 0.006 DBMET03561 | DBMET03561 | |
| 0.03 | 0.645 | 0.146 | Vanilloid 1 agonist | 0.146 0.042 DBMET03561 | DBMET03561 | |
| 0.002 | 0.617 | 0.076 | Free fatty acid receptor 1 antagonist | 0.076 0.004 DBMET03561 | DBMET03561 | |
| 0.018 | 0.635 | 0.188 | DOPA decarboxylase inhibitor | 0.188 0.009 DBMET03561 | DBMET03561 | |
| 0.004 | 0.622 | 0.074 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.074 0.028 DBMET03561 | DBMET03561 | |
| 0.003 | 0.625 | 0.037 | Protein kinase (CK1) epsilon inhibitor | 0.037 0.032 DBMET03561 | DBMET03561 | |
| 0.005 | 0.63 | 0.06 | Protease activated receptor antagonist | 0.06 0.048 DBMET03561 | DBMET03561 | |
| 0.013 | 0.64 | 0.175 | Immunostimulant | 0.175 0.136 DBMET01871 | DBMET01871 | |
| 0.003 | 0.63 | 0.046 | Potassium channel Kv1.3 blocker | 0.046 0.034 DBMET03561 | DBMET03561 | |
| 0.018 | 0.648 | 0.098 | mTOR complex 2 inhibitor | 0.098 0.035 DBMET03561 | DBMET03561 | |
| 0.005 | 0.638 | 0.042 | Estrogen-related receptor gamma antagonist | 0.042 0.005 DBMET03561 | DBMET03561 | |
| 0.002 | 0.638 | 0.02 | Alpha 2b adrenoreceptor agonist | 0.02 0.011 DBMET03561 | DBMET03561 | |
| 0.013 | 0.65 | 0.323 | Hypolipemic | 0.323 0.042 DBMET03561 | DBMET03561 | |
| 0.006 | 0.644 | 0.051 | Epithelial sodium channel blocker | 0.051 0.046 DBMET03561 | DBMET03561 | |
| 0.003 | 0.644 | 0.029 | Prostaglandin D2 antagonist | 0.029 0.012 DBMET03561 | DBMET03561 | |
| 0.004 | 0.645 | 0.067 | Argininosuccinate synthase inhibitor | 0.067 0.032 DBMET03561 | DBMET03561 | |
| 0.004 | 0.648 | 0.32 | Prostaglandin E2 antagonist | 0.32 0.004 DBMET03561 | DBMET03561 | |
| 0.007 | 0.654 | 0.097 | Dopamine beta hydroxylase inhibitor | 0.097 0.004 DBMET03561 | DBMET03561 | |
| 0.004 | 0.652 | 0.054 | Prostacyclin antagonist | 0.054 0.011 DBMET03561 | DBMET03561 | |
| 0.002 | 0.65 | 0.049 | Sodium/glucose cotransporter 2 inhibitor | 0.049 0.006 DBMET03561 | DBMET03561 | |
| 0.004 | 0.655 | 0.047 | Liver X receptor antagonist | 0.047 0.011 DBMET03561 | DBMET03561 | |
| 0.002 | 0.654 | 0.039 | HCV NS5B polymerase inhibitor | 0.039 0.015 DBMET03561 | DBMET03561 | |
| 0.002 | 0.654 | 0.059 | Glutamate (mGluR1a) agonist | 0.059 0.004 DBMET03561 | DBMET03561 | |
| 0.001 | 0.659 | 0.048 | Prostaglandin EP2 agonist | 0.048 0.006 DBMET03561 | DBMET03561 | |
| 0.08 | 0.738 | 0.401 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.401 0.1 DBMET03561 | DBMET03561 | |
| 0.048 | 0.709 | 0.531 | 5 Hydroxytryptamine release stimulant | 0.531 0.023 DBMET03561 | DBMET03561 | |
| 0.01 | 0.672 | 0.113 | Uric acid excretion stimulant | 0.113 0.042 DBMET03561 | DBMET03561 | |
| 0.005 | 0.667 | 0.076 | Glutamate (mGluR) agonist | 0.076 0.033 DBMET03561 | DBMET03561 | |
| 0.003 | 0.665 | 0.044 | Cholesterol ester transfer protein antagonist | 0.044 0.01 DBMET03561 | DBMET03561 | |
| 0.001 | 0.664 | 0.036 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.036 0.01 DBMET03561 | DBMET03561 | |
| 0.053 | 0.715 | 0.247 | Tyrosine 3 hydroxylase inhibitor | 0.247 0.07 DBMET03561 | DBMET03561 | |
| 0.004 | 0.668 | 0.056 | Sphingosine kinase 1 inhibitor | 0.056 0.011 DBMET03561 | DBMET03561 | |
| 0.005 | 0.67 | 0.072 | Beta 2 adrenoreceptor agonist | 0.072 0.016 DBMET03561 | DBMET03561 | |
| 0.03 | 0.697 | 0.245 | RNA-directed DNA polymerase inhibitor | 0.245 0.052 DBMET03561 | DBMET03561 | |
| 0.014 | 0.685 | 0.144 | Adenylate cyclase inhibitor | 0.144 0.049 DBMET03561 | DBMET03561 | |
| 0.024 | 0.695 | 0.095 | ABCA1 expression enhancer | 0.095 0.057 DBMET03561 | DBMET03561 | |
| 0.006 | 0.679 | 0.145 | Alcohol dehydrogenase inhibitor | 0.145 0.022 DBMET03561 | DBMET03561 | |
| 0.019 | 0.695 | 0.301 | Amylase inhibitor | 0.301 0.018 DBMET03561 | DBMET03561 | |
| 0.009 | 0.686 | 0.188 | Myeloperoxidase inhibitor | 0.188 0.006 DBMET03561 | DBMET03561 | |
| 0.008 | 0.684 | 0.08 | Pregnane X receptor antagonist | 0.08 0.006 DBMET03561 | DBMET03561 | |
| 0.004 | 0.682 | 0.069 | Dihydroorotase inhibitor | 0.069 0.012 DBMET03561 | DBMET03561 | |
| 0.02 | 0.697 | 0.229 | Tumour necrosis factor alpha release inhibitor | 0.229 0.086 DBMET03561 | DBMET03561 | |
| 0.01 | 0.687 | 0.054 | CC chemokine 4 receptor antagonist | 0.054 0.022 DBMET03561 | DBMET03561 | |
| 0 | 0.678 | 0.011 | Progesterone receptor A antagonist | 0.011 0.005 DBMET03561 | DBMET03561 | |
| 0.009 | 0.69 | 0.111 | Microtubule formation inhibitor | 0.111 0.073 DBMET03561 | DBMET03561 | |
| 0.01 | 0.693 | 0.151 | Caspase 3 inhibitor | 0.151 0.027 DBMET03561 | DBMET03561 | |
| 0.071 | 0.755 | 0.198 | 5 Hydroxytryptamine 3E antagonist | 0.198 0.065 DBMET03561 | DBMET03561 | |
| 0.004 | 0.689 | 0.083 | Sphingosine kinase inhibitor | 0.083 0.014 DBMET03561 | DBMET03561 | |
| 0.003 | 0.69 | 0.033 | Dipeptidyl peptidase II inhibitor | 0.033 0.022 DBMET03561 | DBMET03561 | |
| 0.004 | 0.694 | 0.048 | Prolyl endopeptidase inhibitor | 0.048 0.039 DBMET03561 | DBMET03561 | |
| 0.028 | 0.719 | 0.116 | DNA repair enzyme inhibitor | 0.116 0.082 DBMET03561 | DBMET03561 | |
| 0.005 | 0.696 | 0.114 | Androgen antagonist | 0.114 0.037 DBMET03561 | DBMET03561 | |
| 0.003 | 0.696 | 0.05 | RNA-directed RNA polymerase inhibitor | 0.05 0.013 DBMET03561 | DBMET03561 | |
| 0.027 | 0.722 | 0.107 | Interleukin 12 antagonist | 0.107 0.043 DBMET03561 | DBMET03561 | |
| 0.003 | 0.7 | 0.026 | Thymidine phosphorylase inhibitor | 0.026 0.017 DBMET03561 | DBMET03561 | |
| 0.003 | 0.701 | 0.11 | Biliverdin reductase inhibitor | 0.11 0.016 DBMET03561 | DBMET03561 | |
| 0.006 | 0.704 | 0.12 | Protein-tyrosine phosphatase inhibitor | 0.12 0.114 DBMET03561 | DBMET03561 | |
| 0.003 | 0.705 | 0.066 | Acetylcholine M5 receptor agonist | 0.066 0.048 DBMET03561 | DBMET03561 | |
| 0.004 | 0.706 | 0.102 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.102 0.014 DBMET03561 | DBMET03561 | |
| 0.004 | 0.71 | 0.126 | Selectin antagonist | 0.126 0.021 DBMET01871 | DBMET01871 | |
| 0.007 | 0.714 | 0.069 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.069 0.005 DBMET03561 | DBMET03561 | |
| 0.01 | 0.717 | 0.155 | AMP-activated protein kinase stimulant | 0.155 0.025 DBMET03561 | DBMET03561 | |
| 0.037 | 0.745 | 0.371 | Apoptosis antagonist | 0.371 0.047 DBMET01871 0.304 0.083 DBMET03561 | DBMET01871 | |
| 0.002 | 0.709 | 0.033 | Progesterone antagonist | 0.033 0.027 DBMET03561 | DBMET03561 | |
| 0.002 | 0.71 | 0.145 | TRPM8 blocker | 0.145 0.005 DBMET03561 | DBMET03561 | |
| 0.004 | 0.715 | 0.074 | Aryl hydrocarbon receptor antagonist | 0.074 0.033 DBMET03561 | DBMET03561 | |
| 0.016 | 0.728 | 0.151 | Melanin inhibitor | 0.151 0.08 DBMET03561 | DBMET03561 | |
| 0.004 | 0.718 | 0.281 | Prostaglandin antagonist | 0.281 0.005 DBMET03561 | DBMET03561 | |
| 0.011 | 0.726 | 0.161 | Nav1.5 sodium channel blocker | 0.161 0.022 DBMET03561 | DBMET03561 | |
| 0.004 | 0.721 | 0.036 | Glutamate (mGluR1) agonist | 0.036 0.007 DBMET03561 | DBMET03561 | |
| 0.022 | 0.739 | 0.18 | Tumour necrosis factor antagonist | 0.18 0.067 DBMET03561 | DBMET03561 | |
| 0.011 | 0.729 | 0.097 | Glutamate dehydrogenase inhibitor | 0.097 0.032 DBMET03561 | DBMET03561 | |
| 0.004 | 0.723 | 0.098 | TRKA antagonist | 0.098 0.092 DBMET03561 | DBMET03561 | |
| 0.008 | 0.729 | 0.171 | Creatine kinase inhibitor | 0.171 0.017 DBMET03561 | DBMET03561 | |
| 0.009 | 0.73 | 0.218 | Alpha-glucosidase inhibitor | 0.218 0.208 DBMET03561 | DBMET03561 | |
| 0.002 | 0.723 | 0.041 | Nicotinic acid receptor 2 antagonist | 0.041 0.005 DBMET03561 | DBMET03561 | |
| 0.001 | 0.723 | 0.017 | Telomerase stimulant | 0.017 0.012 DBMET03561 | DBMET03561 | |
| 0.006 | 0.729 | 0.127 | Potassium channel intermediate-conductance Ca-activated blocker | 0.127 0.005 DBMET03561 | DBMET03561 | |
| 0.003 | 0.726 | 0.154 | Monophenol monooxygenase inhibitor | 0.154 0.046 DBMET03561 | DBMET03561 | |
| 0.002 | 0.725 | 0.043 | Peroxisome proliferator-activated receptor alpha agonist | 0.043 0.039 DBMET03561 | DBMET03561 | |
| 0.005 | 0.729 | 0.069 | Adenylate cyclase 1 inhibitor | 0.069 0.013 DBMET03561 | DBMET03561 | |
| 0.002 | 0.726 | 0.044 | Methionyl aminopeptidase 2 inhibitor | 0.044 0.008 DBMET03561 | DBMET03561 | |
| 0.004 | 0.729 | 0.04 | Glutamate (mGluR3) agonist | 0.04 0.01 DBMET03561 | DBMET03561 | |
| 0.01 | 0.737 | 0.122 | Keratolytic | 0.122 0.021 DBMET03561 | DBMET03561 | |
| 0.006 | 0.735 | 0.192 | MAP kinase kinase inhibitor | 0.192 0.031 DBMET03561 | DBMET03561 | |
| 0.009 | 0.74 | 0.087 | GABA C receptor rho-1 antagonist | 0.087 0.084 DBMET03561 | DBMET03561 | |
| 0.014 | 0.746 | 0.152 | Adenylate cyclase stimulant | 0.152 0.059 DBMET03561 | DBMET03561 | |
| 0.003 | 0.735 | 0.145 | Phosphofructokinase-1 inhibitor | 0.145 0.019 DBMET03561 | DBMET03561 | |
| 0.014 | 0.749 | 0.17 | NADH dehydrogenase inhibitor | 0.17 0.014 DBMET03561 | DBMET03561 | |
| 0.022 | 0.756 | 0.083 | Estrogen-related receptor beta agonist | 0.083 0.056 DBMET03561 | DBMET03561 | |
| 0.007 | 0.743 | 0.117 | GABA C receptor antagonist | 0.117 0.056 DBMET03561 | DBMET03561 | |
| 0.005 | 0.741 | 0.112 | Cyclooxygenase 2 inhibitor | 0.112 0.089 DBMET03561 | DBMET03561 | |
| 0.005 | 0.743 | 0.263 | Anticonvulsant | 0.263 0.052 DBMET03561 | DBMET03561 | |
| 0.002 | 0.739 | 0.082 | Glutamate (mGluR group II) antagonist | 0.082 0.006 DBMET03561 | DBMET03561 | |
| 0.007 | 0.745 | 0.066 | Protease 3C (Human rhinovirus) inhibitor | 0.066 0.042 DBMET03561 | DBMET03561 | |
| 0.004 | 0.743 | 0.191 | Catalase inhibitor | 0.191 0.017 DBMET03561 | DBMET03561 | |
| 0.006 | 0.746 | 0.139 | Cyclooxygenase 1 inhibitor | 0.139 0.064 DBMET03561 | DBMET03561 | |
| 0.002 | 0.742 | 0.024 | Acid ceramidase inhibitor | 0.024 0.023 DBMET03561 | DBMET03561 | |
| 0.003 | 0.744 | 0.099 | Carbamoyl phosphate synthetase inhibitor | 0.099 0.021 DBMET03561 | DBMET03561 | |
| 0.002 | 0.743 | 0.058 | Vascular adhesion protein 1 inhibitor | 0.058 0.011 DBMET03561 | DBMET03561 | |
| 0.01 | 0.752 | 0.061 | CD45 antagonist | 0.061 0.02 DBMET03561 | DBMET03561 | |
| 0.018 | 0.761 | 0.102 | D-Ala-D-Ala ligase inhibitor | 0.102 0.027 DBMET03561 | DBMET03561 | |
| 0.017 | 0.76 | 0.226 | Transcription factor STAT inhibitor | 0.226 0.106 DBMET03561 | DBMET03561 | |
| 0.004 | 0.747 | 0.091 | MAP kinase kinase kinase inhibitor | 0.091 0.075 DBMET03561 | DBMET03561 | |
| 0.012 | 0.755 | 0.118 | Nav1.2 sodium channel blocker | 0.118 0.085 DBMET03561 | DBMET03561 | |
| 0.007 | 0.752 | 0.077 | GABA B receptor agonist | 0.077 0.049 DBMET03561 | DBMET03561 | |
| 0.004 | 0.75 | 0.141 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.141 0.022 DBMET03561 | DBMET03561 | |
| 0.009 | 0.756 | 0.185 | Nav1.6 sodium channel blocker | 0.185 0.025 DBMET03561 | DBMET03561 | |
| 0.012 | 0.76 | 0.109 | Vanilloid 4 agonist | 0.109 0.011 DBMET03561 | DBMET03561 | |
| 0.009 | 0.757 | 0.176 | Toll-Like receptor 2 antagonist | 0.176 0.036 DBMET03561 | DBMET03561 | |
| 0.005 | 0.754 | 0.174 | Beta amyloid protein antagonist | 0.174 0.027 DBMET03561 | DBMET03561 | |
| 0.002 | 0.751 | 0.055 | Glutamate (mGluR2) antagonist | 0.055 0.007 DBMET03561 | DBMET03561 | |
| 0.009 | 0.758 | 0.083 | Bromodomain-containing protein 2 inhibitor | 0.083 0.069 DBMET03561 | DBMET03561 | |
| 0.003 | 0.752 | 0.062 | Prostaglandin-E synthase inhibitor | 0.062 0.061 DBMET03561 | DBMET03561 | |
| 0.006 | 0.757 | 0.066 | Botulinum neurotoxin type A inhibitor | 0.066 0.03 DBMET03561 | DBMET03561 | |
| 0.012 | 0.763 | 0.299 | Triose-phosphate isomerase inhibitor | 0.299 0.005 DBMET03561 | DBMET03561 | |
| 0.011 | 0.765 | 0.247 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.247 0.044 DBMET03561 | DBMET03561 | |
| 0.001 | 0.755 | 0.011 | Imidazoline I2 receptor antagonist | 0.011 0.008 DBMET03561 | DBMET03561 | |
| 0.009 | 0.764 | 0.491 | Alpha-N-acetylglucosaminidase inhibitor | 0.491 0.005 DBMET03561 | DBMET03561 | |
| 0.03 | 0.786 | 0.273 | GABA C receptor rho-3 antagonist | 0.273 0.135 DBMET03561 | DBMET03561 | |
| 0.003 | 0.76 | 0.08 | Dihydroorotate dehydrogenase inhibitor | 0.08 0.018 DBMET03561 | DBMET03561 | |
| 0.008 | 0.766 | 0.269 | Mannose-6-phosphate isomerase inhibitor | 0.269 0.009 DBMET03561 | DBMET03561 | |
| 0.001 | 0.76 | 0.023 | Nicotinic acid receptor 1 antagonist | 0.023 0.007 DBMET03561 | DBMET03561 | |
| 0.012 | 0.771 | 0.195 | Hemostatic | 0.195 0.034 DBMET03561 | DBMET03561 | |
| 0.002 | 0.764 | 0.174 | MAO B inhibitor | 0.174 0.03 DBMET03561 | DBMET03561 | |
| 0.005 | 0.768 | 0.113 | Sphingosine 1-phosphate receptor antagonist | 0.113 0.015 DBMET03561 | DBMET03561 | |
| 0.003 | 0.768 | 0.045 | Stearoyl-CoA desaturase inhibitor | 0.045 0.029 DBMET03561 | DBMET03561 | |
| 0.002 | 0.768 | 0.063 | Sphingosine 1-phosphate receptor agonist | 0.063 0.015 DBMET03561 | DBMET03561 | |
| 0.01 | 0.775 | 0.104 | Potassium channel (Ca-activated) activator | 0.104 0.052 DBMET03561 | DBMET03561 | |
| 0.004 | 0.77 | 0.073 | Peroxisome proliferator-activated receptor gamma antagonist | 0.073 0.047 DBMET03561 | DBMET03561 | |
| 0.003 | 0.769 | 0.195 | MAO inhibitor | 0.195 0.042 DBMET03561 | DBMET03561 | |
| 0.017 | 0.784 | 0.216 | Immunosuppressant | 0.216 0.181 DBMET03561 | DBMET03561 | |
| 0.004 | 0.77 | 0.094 | 5 Hydroxytryptamine 2 antagonist | 0.094 0.077 DBMET03561 | DBMET03561 | |
| 0.005 | 0.773 | 0.123 | Macrophage migration inhibitory factor inhibitor | 0.123 0.024 DBMET03561 | DBMET03561 | |
| 0.001 | 0.769 | 0.036 | CXC chemokine 2 receptor antagonist | 0.036 0.009 DBMET03561 | DBMET03561 | |
| 0.051 | 0.821 | 0.446 | 5 Hydroxytryptamine uptake stimulant | 0.446 0.008 DBMET03561 | DBMET03561 | |
| 0.005 | 0.774 | 0.096 | Glycine receptor antagonist | 0.096 0.036 DBMET03561 | DBMET03561 | |
| 0.004 | 0.775 | 0.103 | Phenylalanine 4-hydroxylase inhibitor | 0.103 0.024 DBMET03561 | DBMET03561 | |
| 0.006 | 0.778 | 0.142 | Cyclooxygenase inhibitor | 0.142 0.076 DBMET03561 | DBMET03561 | |
| 0.004 | 0.777 | 0.07 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.07 0.059 DBMET03561 | DBMET03561 | |
| 0.005 | 0.781 | 0.043 | Glutamate (mGluR group III) agonist | 0.043 0.029 DBMET03561 | DBMET03561 | |
| 0.004 | 0.782 | 0.083 | Carbonic anhydrase VA inhibitor | 0.083 0.034 DBMET03561 | DBMET03561 | |
| 0.004 | 0.783 | 0.051 | Liver X receptor agonist | 0.051 0.022 DBMET03561 | DBMET03561 | |
| 0.006 | 0.786 | 0.195 | GABA C receptor agonist | 0.195 0.021 DBMET03561 | DBMET03561 | |
| 0.001 | 0.783 | 0.019 | Imidazoline I1 receptor antagonist | 0.019 0.017 DBMET03561 | DBMET03561 | |
| 0.001 | 0.783 | 0.034 | Peroxisome proliferator-activated receptor delta agonist | 0.034 0.022 DBMET03561 | DBMET03561 | |
| 0.002 | 0.784 | 0.075 | Carbonic anhydrase VB inhibitor | 0.075 0.025 DBMET03561 | DBMET03561 | |
| 0.003 | 0.787 | 0.079 | Xanthine dehydrogenase inhibitor | 0.079 0.025 DBMET03561 | DBMET03561 | |
| 0.004 | 0.788 | 0.047 | Beta adrenoreceptor agonist | 0.047 0.024 DBMET03561 | DBMET03561 | |
| 0.018 | 0.804 | 0.694 | Cyclophilin D inhibitor | 0.456 0.065 DBMET01871 0.694 0.015 DBMET03561 | DBMET03561 | |
| 0.003 | 0.79 | 0.082 | Carbonic anhydrase V inhibitor | 0.082 0.034 DBMET03561 | DBMET03561 | |
| 0.004 | 0.791 | 0.076 | Sphingosine 1-phosphate receptor 1 antagonist | 0.076 0.015 DBMET03561 | DBMET03561 | |
| 0.006 | 0.794 | 0.056 | Cyclin D1 inhibitor | 0.056 0.05 DBMET03561 | DBMET03561 | |
| 0.014 | 0.802 | 0.272 | Neurotrophic factor enhancer | 0.272 0.027 DBMET03561 | DBMET03561 | |
| 0.009 | 0.798 | 0.076 | Purinergic P2X1 antagonist | 0.076 0.027 DBMET03561 | DBMET03561 | |
| 0.002 | 0.792 | 0.033 | ATP citrate lysase inhibitor | 0.033 0.021 DBMET03561 | DBMET03561 | |
| 0.007 | 0.799 | 0.102 | Beta glucuronidase inhibitor | 0.102 0.067 DBMET03561 | DBMET03561 | |
| 0.003 | 0.795 | 0.108 | Nav1.7 sodium channel blocker | 0.108 0.02 DBMET03561 | DBMET03561 | |
| 0.003 | 0.796 | 0.044 | Cholesterol esterase inhibitor | 0.044 0.039 DBMET03561 | DBMET03561 | |
| 0.008 | 0.801 | 0.056 | Dihydroorotate oxidase inhibitor | 0.056 0.036 DBMET03561 | DBMET03561 | |
| 0.001 | 0.795 | 0.034 | Glucagon receptor antagonist | 0.034 0.017 DBMET03561 | DBMET03561 | |
| 0.006 | 0.8 | 0.039 | Vanilloid 3 antagonist | 0.039 0.024 DBMET03561 | DBMET03561 | |
| 0.005 | 0.801 | 0.137 | Mucolytic | 0.137 0.04 DBMET03561 | DBMET03561 | |
| 0 | 0.796 | 0.013 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.013 0.01 DBMET03561 | DBMET03561 | |
| 0.017 | 0.813 | 0.191 | Interferon gamma antagonist | 0.191 0.044 DBMET03561 | DBMET03561 | |
| 0.029 | 0.826 | 0.163 | Ca2+-transporting ATPase inhibitor | 0.163 0.02 DBMET03561 | DBMET03561 | |
| 0.002 | 0.8 | 0.085 | Acyl-CoA dehydrogenase inhibitor | 0.085 0.02 DBMET03561 | DBMET03561 | |
| 0.003 | 0.803 | 0.214 | Porphobilinogen synthase inhibitor | 0.214 0.01 DBMET03561 | DBMET03561 | |
| 0.004 | 0.805 | 0.086 | Glucosylceramidase inhibitor | 0.086 0.012 DBMET03561 | DBMET03561 | |
| 0.027 | 0.828 | 0.182 | Growth factor agonist | 0.182 0.083 DBMET03561 | DBMET03561 | |
| 0.01 | 0.812 | 0.172 | Insulin secretagoues | 0.172 0.054 DBMET03561 | DBMET03561 | |
| 0.009 | 0.812 | 0.175 | Antipruritic | 0.175 0.069 DBMET03561 | DBMET03561 | |
| 0.004 | 0.807 | 0.059 | Potassium channel (ATP-sensitive) activator | 0.059 0.017 DBMET03561 | DBMET03561 | |
| 0.008 | 0.812 | 0.219 | Transcription factor NF kappa B inhibitor | 0.219 0.151 DBMET03561 | DBMET03561 | |
| 0.001 | 0.805 | 0.028 | Potassium channel small-conductance Ca-activated activator | 0.028 0.025 DBMET03561 | DBMET03561 | |
| 0.018 | 0.822 | 0.178 | CF transmembrane conductance regulator agonist | 0.178 0.038 DBMET03561 | DBMET03561 | |
| 0.001 | 0.806 | 0.05 | Ornithine carbamoyltransferase inhibitor | 0.05 0.039 DBMET03561 | DBMET03561 | |
| 0.002 | 0.808 | 0.058 | Nicotinic acid receptor agonist | 0.058 0.012 DBMET03561 | DBMET03561 | |
| 0.004 | 0.809 | 0.062 | Potassium channel (Inward rectifier) activator | 0.062 0.018 DBMET03561 | DBMET03561 | |
| 0.002 | 0.809 | 0.093 | Thromboxane antagonist | 0.093 0.014 DBMET03561 | DBMET03561 | |
| 0.002 | 0.809 | 0.035 | Prostaglandin EP4 antagonist | 0.035 0.013 DBMET03561 | DBMET03561 | |
| 0.01 | 0.818 | 0.101 | Granulocyte macrophage colony stimulating factor agonist | 0.101 0.033 DBMET03561 | DBMET03561 | |
| 0.004 | 0.814 | 0.076 | Aminopeptidase I inhibitor | 0.076 0.046 DBMET03561 | DBMET03561 | |
| 0.009 | 0.819 | 0.117 | Anabolic | 0.117 0.043 DBMET03561 | DBMET03561 | |
| 0.004 | 0.814 | 0.062 | Carbonic anhydrase stimulant | 0.062 0.038 DBMET03561 | DBMET03561 | |
| 0.008 | 0.818 | 0.26 | Antiamyloidogenic | 0.26 0.067 DBMET03561 | DBMET03561 | |
| 0.003 | 0.813 | 0.151 | Sphingosine 1-phosphate receptor 4 agonist | 0.151 0.008 DBMET03561 | DBMET03561 | |
| 0.002 | 0.812 | 0.078 | Alcohol oxidase inhibitor | 0.078 0.025 DBMET03561 | DBMET03561 | |
| 0.004 | 0.815 | 0.194 | Sodium channel blocker | 0.194 0.035 DBMET03561 | DBMET03561 | |
| 0.007 | 0.82 | 0.09 | Prolactin inhibitor | 0.09 0.067 DBMET03561 | DBMET03561 | |
| 0.001 | 0.814 | 0.04 | Fumarate hydratase inhibitor | 0.04 0.019 DBMET03561 | DBMET03561 | |
| 0.027 | 0.84 | 0.506 | Caspase 9 stimulant | 0.506 0.057 DBMET03561 | DBMET03561 | |
| 0.012 | 0.827 | 0.16 | Peroxidase inhibitor | 0.16 0.073 DBMET03561 | DBMET03561 | |
| 0.004 | 0.819 | 0.163 | MAP kinase kinase 1 inhibitor | 0.163 0.012 DBMET03561 | DBMET03561 | |
| 0.017 | 0.833 | 0.147 | Adenylate kinase inhibitor | 0.147 0.027 DBMET03561 | DBMET03561 | |
| 0.004 | 0.822 | 0.056 | Cytokine production stimulant | 0.056 0.018 DBMET03561 | DBMET03561 | |
| 0.004 | 0.822 | 0.105 | Expectorant | 0.105 0.063 DBMET03561 | DBMET03561 | |
| 0.003 | 0.823 | 0.048 | Diacylglycerol O-acyltransferase inhibitor | 0.048 0.039 DBMET03561 | DBMET03561 | |
| 0.005 | 0.824 | 0.073 | Interferon inducer | 0.073 0.03 DBMET03561 | DBMET03561 | |
| 0 | 0.82 | 0.011 | Thromboxane agonist | 0.011 0.007 DBMET03561 | DBMET03561 | |
| 0.002 | 0.823 | 0.085 | Glutamate (mGluR3) antagonist | 0.085 0.005 DBMET03561 | DBMET03561 | |
| 0.002 | 0.823 | 0.096 | Glutamate decarboxylase inhibitor | 0.096 0.032 DBMET03561 | DBMET03561 | |
| 0.002 | 0.823 | 0.04 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.04 0.016 DBMET03561 | DBMET03561 | |
| 0.006 | 0.827 | 0.182 | Arachidonic acid antagonist | 0.182 0.052 DBMET03561 | DBMET03561 | |
| 0.005 | 0.826 | 0.303 | Ferrochelatase inhibitor | 0.303 0.007 DBMET03561 | DBMET03561 | |
| 0.005 | 0.826 | 0.134 | Cystathionine beta-synthase inhibitor | 0.134 0.049 DBMET03561 | DBMET03561 | |
| 0.016 | 0.838 | 0.203 | Hexokinase inhibitor | 0.203 0.034 DBMET03561 | DBMET03561 | |
| 0.018 | 0.84 | 0.063 | Calcium channel P-type blocker | 0.063 0.046 DBMET03561 | DBMET03561 | |
| 0.003 | 0.827 | 0.108 | Sphingosine kinase 2 inhibitor | 0.108 0.006 DBMET03561 | DBMET03561 | |
| 0.003 | 0.827 | 0.138 | Histidine decarboxylase inhibitor | 0.138 0.022 DBMET03561 | DBMET03561 | |
| 0.011 | 0.835 | 0.215 | Hypoxia-inducible factor 1 alpha inhibitor | 0.215 0.134 DBMET03561 | DBMET03561 | |
| 0.004 | 0.828 | 0.221 | Sodium channel (voltage-gated) blocker | 0.221 0.022 DBMET03561 | DBMET03561 | |
| 0.008 | 0.833 | 0.124 | Aminopeptidase B inhibitor | 0.124 0.05 DBMET03561 | DBMET03561 | |
| 0.004 | 0.829 | 0.195 | Lipoxygenase inhibitor | 0.195 0.146 DBMET03561 | DBMET03561 | |
| 0.034 | 0.86 | 0.133 | Heat shock protein 70 antagonist | 0.133 0.106 DBMET03561 | DBMET03561 | |
| 0.004 | 0.83 | 0.04 | Kainate receptor agonist | 0.04 0.032 DBMET03561 | DBMET03561 | |
| 0.005 | 0.832 | 0.082 | Glucose-6-phosphate isomerase inhibitor | 0.082 0.008 DBMET03561 | DBMET03561 | |
| 0.005 | 0.837 | 0.056 | I kappa B kinase 2 inhibitor | 0.056 0.055 DBMET03561 | DBMET03561 | |
| 0.001 | 0.836 | 0.072 | Liver X receptor beta antagonist | 0.072 0.004 DBMET03561 | DBMET03561 | |
| 0.004 | 0.84 | 0.086 | Interferon agonist | 0.086 0.043 DBMET03561 | DBMET03561 | |
| 0.004 | 0.843 | 0.029 | Complement factor 1s inhibitor | 0.029 0.01 DBMET03561 | DBMET03561 | |
| 0.019 | 0.859 | 0.333 | 5 Hydroxytryptamine release inhibitor | 0.333 0.131 DBMET03561 | DBMET03561 | |
| 0.001 | 0.843 | 0.047 | Sphingosine 1-phosphate receptor 1 agonist | 0.047 0.023 DBMET03561 | DBMET03561 | |
| 0.001 | 0.843 | 0.028 | MAP3K8 inhibitor | 0.028 0.023 DBMET03561 | DBMET03561 | |
| 0.028 | 0.87 | 0.337 | Calcium channel activator | 0.337 0.059 DBMET03561 | DBMET03561 | |
| 0.001 | 0.843 | 0.031 | Phosphoglycerate kinase inhibitor | 0.031 0.029 DBMET03561 | DBMET03561 | |
| 0.006 | 0.848 | 0.084 | Ornithine decarboxylase inhibitor | 0.084 0.063 DBMET03561 | DBMET03561 | |
| 0.001 | 0.844 | 0.025 | Vanilloid 2 agonist | 0.025 0.019 DBMET03561 | DBMET03561 | |
| 0.001 | 0.844 | 0.038 | Alpha 1d adrenoreceptor agonist | 0.038 0.027 DBMET03561 | DBMET03561 | |
| 0.012 | 0.856 | 0.216 | Phospholipase C inhibitor | 0.216 0.035 DBMET03561 | DBMET03561 | |
| 0.02 | 0.864 | 0.215 | Histamine release inhibitor | 0.215 0.185 DBMET03561 | DBMET03561 | |
| 0.002 | 0.847 | 0.045 | Leukotriene C4 antagonist | 0.045 0.015 DBMET03561 | DBMET03561 | |
| 0.001 | 0.846 | 0.048 | GABA uptake inhibitor | 0.048 0.017 DBMET03561 | DBMET03561 | |
| 0.007 | 0.852 | 0.145 | Cathepsin H inhibitor | 0.145 0.05 DBMET03561 | DBMET03561 | |
| 0.004 | 0.85 | 0.202 | MAP kinase kinase 2 inhibitor | 0.202 0.08 DBMET03561 | DBMET03561 | |
| 0.005 | 0.851 | 0.054 | Adenosine deaminase inhibitor | 0.054 0.027 DBMET03561 | DBMET03561 | |
| 0.007 | 0.856 | 0.2 | Succinate dehydrogenase inhibitor | 0.2 0.048 DBMET03561 | DBMET03561 | |
| 0.011 | 0.861 | 0.16 | Nav1.3 sodium channel blocker | 0.16 0.042 DBMET03561 | DBMET03561 | |
| 0.007 | 0.858 | 0.068 | Glycine receptor agonist | 0.068 0.06 DBMET03561 | DBMET03561 | |
| 0.003 | 0.854 | 0.157 | Glutamate receptor agonist | 0.157 0.016 DBMET03561 | DBMET03561 | |
| 0.005 | 0.858 | 0.07 | Estrogen receptor alpha antagonist | 0.07 0.067 DBMET03561 | DBMET03561 | |
| 0.007 | 0.86 | 0.089 | Glutamate (mGluR6) antagonist | 0.089 0.016 DBMET03561 | DBMET03561 | |
| 0.004 | 0.858 | 0.183 | Sphingosine 1-phosphate receptor 2 antagonist | 0.183 0.014 DBMET03561 | DBMET03561 | |
| 0.008 | 0.863 | 0.173 | Protein kinase stimulant | 0.173 0.054 DBMET03561 | DBMET03561 | |
| 0.002 | 0.857 | 0.083 | Liver X receptor alpha agonist | 0.083 0.006 DBMET03561 | DBMET03561 | |
| 0.014 | 0.87 | 0.197 | Superoxide dismutase inhibitor | 0.197 0.12 DBMET03561 | DBMET03561 | |
| 0.003 | 0.86 | 0.117 | Alkaline phosphatase inhibitor | 0.117 0.09 DBMET03561 | DBMET03561 | |
| 0.002 | 0.86 | 0.086 | Aconitate hydratase inhibitor | 0.086 0.012 DBMET03561 | DBMET03561 | |
| 0.009 | 0.867 | 0.134 | Cytokine production inhibitor | 0.134 0.076 DBMET03561 | DBMET03561 | |
| 0.005 | 0.863 | 0.027 | Hedgehog signaling activator | 0.027 0.019 DBMET03561 | DBMET03561 | |
| 0.002 | 0.861 | 0.067 | Leukotriene C antagonist | 0.067 0.018 DBMET03561 | DBMET03561 | |
| 0.004 | 0.862 | 0.053 | Glutamate (mGluR8) agonist | 0.053 0.01 DBMET03561 | DBMET03561 | |
| 0.009 | 0.87 | 0.455 | Cholesterol antagonist | 0.455 0.04 DBMET03561 | DBMET03561 | |
| 0.001 | 0.863 | 0.055 | Diamine oxidase inhibitor | 0.055 0.012 DBMET03561 | DBMET03561 | |
| 0.002 | 0.866 | 0.091 | Na+ K+ transporting ATPase inhibitor | 0.091 0.04 DBMET03561 | DBMET03561 | |
| 0.001 | 0.866 | 0.041 | Geranyltranstransferase inhibitor | 0.041 0.035 DBMET03561 | DBMET03561 | |
| 0.003 | 0.868 | 0.104 | Adrenaline agonist | 0.104 0.034 DBMET03561 | DBMET03561 | |
| 0.003 | 0.869 | 0.065 | Heparanase inhibitor | 0.065 0.016 DBMET03561 | DBMET03561 | |
| 0.003 | 0.87 | 0.077 | Glutamate (mGluR7) antagonist | 0.077 0.031 DBMET03561 | DBMET03561 | |
| 0.012 | 0.879 | 0.119 | Interleukin 1b antagonist | 0.119 0.063 DBMET03561 | DBMET03561 | |
| 0.001 | 0.869 | 0.079 | Liver X receptor beta agonist | 0.079 0.006 DBMET03561 | DBMET03561 | |
| 0.006 | 0.875 | 0.225 | Antithrombotic | 0.225 0.148 DBMET03561 | DBMET03561 | |
| 0.003 | 0.873 | 0.054 | Potassium channel (Inward rectifier) blocker | 0.054 0.029 DBMET03561 | DBMET03561 | |
| 0 | 0.871 | 0.032 | G-protein-coupled receptor 120 agonist | 0.032 0.005 DBMET03561 | DBMET03561 | |
| 0.022 | 0.894 | 0.225 | Glutamate release inhibitor | 0.225 0.004 DBMET03561 | DBMET03561 | |
| 0.003 | 0.876 | 0.158 | Pyruvate kinase inhibitor | 0.158 0.109 DBMET03561 | DBMET03561 | |
| 0.008 | 0.881 | 0.102 | Interleukin 8 antagonist | 0.102 0.091 DBMET03561 | DBMET03561 | |
| 0.003 | 0.878 | 0.051 | Retinoid X receptor antagonist | 0.051 0.011 DBMET03561 | DBMET03561 | |
| 0.001 | 0.876 | 0.049 | Farnesoid X receptor agonist | 0.049 0.015 DBMET03561 | DBMET03561 | |
| 0.004 | 0.879 | 0.129 | Cholesterol synthesis inhibitor | 0.129 0.057 DBMET03561 | DBMET03561 | |
| 0.003 | 0.879 | 0.045 | Retinoid X alpha receptor antagonist | 0.045 0.01 DBMET03561 | DBMET03561 | |
| 0.004 | 0.88 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.057 DBMET03561 | DBMET03561 | |
| 0.001 | 0.878 | 0.076 | Thromboxane A2 antagonist | 0.076 0.017 DBMET03561 | DBMET03561 | |
| 0.004 | 0.882 | 0.184 | Spasmolytic | 0.184 0.134 DBMET03561 | DBMET03561 | |
| 0.004 | 0.882 | 0.149 | I kappa B kinase epsilon inhibitor | 0.149 0.121 DBMET03561 | DBMET03561 | |
| 0.003 | 0.882 | 0.085 | GABA aminotransferase inhibitor | 0.085 0.04 DBMET03561 | DBMET03561 | |
| 0.008 | 0.888 | 0.122 | Interleukin 1 antagonist | 0.122 0.085 DBMET03561 | DBMET03561 | |
| 0.005 | 0.885 | 0.098 | Xanthine oxidase inhibitor | 0.098 0.062 DBMET03561 | DBMET03561 | |
| 0.007 | 0.887 | 0.094 | Sphingomyelinase inhibitor | 0.094 0.066 DBMET03561 | DBMET03561 | |
| 0.001 | 0.882 | 0.02 | Lysophosphatidic acid 1 receptor antagonist | 0.02 0.018 DBMET03561 | DBMET03561 | |
| 0.004 | 0.886 | 0.183 | Transcription factor STAT3 inhibitor | 0.183 0.159 DBMET03561 | DBMET03561 | |
| 0.006 | 0.89 | 0.165 | Carbonic anhydrase XV inhibitor | 0.165 0.026 DBMET03561 | DBMET03561 | |
| 0.003 | 0.888 | 0.198 | Calpain 2 inhibitor | 0.198 0.189 DBMET03561 | DBMET03561 | |
| 0.002 | 0.887 | 0.063 | Beta adrenoreceptor antagonist | 0.063 0.05 DBMET03561 | DBMET03561 | |
| 0.003 | 0.889 | 0.077 | Lysine-specific demethylase 1A inhibitor | 0.077 0.014 DBMET03561 | DBMET03561 | |
| 0.001 | 0.887 | 0.032 | Glucose-dependent insulinotropic receptor agonist | 0.032 0.028 DBMET03561 | DBMET03561 | |
| 0.01 | 0.896 | 0.239 | Vasodilator, coronary | 0.239 0.145 DBMET03561 | DBMET03561 | |
| 0.009 | 0.899 | 0.193 | HIV-1 integrase (Overall Integration) inhibitor | 0.193 0.013 DBMET03561 | DBMET03561 | |
| 0.008 | 0.898 | 0.101 | Phosphodiesterase 6D inhibitor | 0.101 0.05 DBMET03561 | DBMET03561 | |
| 0.008 | 0.899 | 0.159 | ATPase inhibitor | 0.159 0.087 DBMET03561 | DBMET03561 | |
| 0.003 | 0.894 | 0.075 | Potassium channel (ATP-sensitive) blocker | 0.075 0.033 DBMET03561 | DBMET03561 | |
| 0.001 | 0.892 | 0.019 | Retinoid X beta receptor antagonist | 0.019 0.018 DBMET03561 | DBMET03561 | |
| 0.01 | 0.903 | 0.177 | Neuropeptide Y2 antagonist | 0.177 0.166 DBMET03561 | DBMET03561 | |
| 0.011 | 0.907 | 0.165 | Photosensitizer | 0.165 0.023 DBMET03561 | DBMET03561 | |
| 0.001 | 0.9 | 0.056 | Leukotriene B4 antagonist | 0.056 0.033 DBMET03561 | DBMET03561 | |
| 0.004 | 0.903 | 0.274 | Non-steroidal antiinflammatory agent | 0.274 0.034 DBMET03561 | DBMET03561 | |
| 0.006 | 0.908 | 0.124 | Sphingosine 1-phosphate receptor 4 antagonist | 0.124 0.065 DBMET03561 | DBMET03561 | |
| 0.002 | 0.904 | 0.146 | Aryl hydrocarbon receptor agonist | 0.146 0.138 DBMET03561 | DBMET03561 | |
| 0.002 | 0.907 | 0.052 | Lysophosphatidic acid 3 receptor antagonist | 0.052 0.032 DBMET03561 | DBMET03561 | |
| 0.004 | 0.912 | 0.181 | Sphingosine 1-phosphate receptor 5 antagonist | 0.181 0.023 DBMET03561 | DBMET03561 | |
| 0.004 | 0.912 | 0.041 | Heme oxygenase inhibitor | 0.041 0.035 DBMET03561 | DBMET03561 | |
| 0.006 | 0.917 | 0.096 | Carbonic anhydrase VI inhibitor | 0.096 0.042 DBMET03561 | DBMET03561 | |
| 0.001 | 0.913 | 0.054 | G protein-coupled receptor agonist | 0.054 0.015 DBMET03561 | DBMET03561 | |
| 0 | 0.913 | 0.035 | Kynurenine 3 monooxygenase inhibitor | 0.035 0.012 DBMET03561 | DBMET03561 | |
| 0.007 | 0.919 | 0.079 | Exportin-1 inhibitor | 0.079 0.027 DBMET03561 | DBMET03561 | |
| 0.003 | 0.92 | 0.203 | Insulin sensitizer | 0.203 0.071 DBMET03561 | DBMET03561 | |
| 0.004 | 0.921 | 0.152 | Pregnane X receptor agonist | 0.152 0.049 DBMET03561 | DBMET03561 | |
| 0.004 | 0.922 | 0.149 | Neurotensin receptor agonist | 0.149 0.104 DBMET03561 | DBMET03561 | |
| 0.005 | 0.925 | 0.199 | Aldehyde oxidase inhibitor | 0.199 0.105 DBMET03561 | DBMET03561 | |
| 0.003 | 0.931 | 0.077 | Carbonic anhydrase XIII inhibitor | 0.077 0.052 DBMET03561 | DBMET03561 | |
| 0.006 | 0.936 | 0.091 | Bile acid receptor antagonist | 0.091 0.07 DBMET03561 | DBMET03561 | |
| 0.003 | 0.933 | 0.213 | Anesthetic general | 0.213 0.068 DBMET03561 | DBMET03561 | |
| 0.006 | 0.938 | 0.114 | Carbonic anhydrase III inhibitor | 0.114 0.049 DBMET03561 | DBMET03561 | |
| 0.006 | 0.94 | 0.249 | Vasodilator, peripheral | 0.249 0.128 DBMET03561 | DBMET03561 | |
| 0.004 | 0.947 | 0.101 | MDM2 inhibitor | 0.101 0.007 DBMET03561 | DBMET03561 | |
| 0.002 | 0.946 | 0.106 | Gastric antisecretory | 0.106 0.058 DBMET03561 | DBMET03561 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |